Select Language
Free Registration

Anti-CD3 Antibody

Product Inquiry

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
Plerixafor/Tacrolimus HydrateMRG-001(MedRegen); AMD3100+FK506Phase 2 ClinicalMedRegen LLCHepatitis, Alcoholic; Motor Neuron Disease; Cytokine Release Syndrome; Respiratory Tract Diseases; Coronavirus Disease 2019 (COVID-19); Respiratory Distress Syndrome, Adult; Abdominal Injuries; Wounds and Injuries; Amyotrophic Lateral Sclerosis; Respiratory Insufficiency
Details
RimiducidAP-1903Phase 2 ClinicalAriad Pharmaceuticals Inc, Bellicum Pharmaceuticals IncNeuroblastoma; Multiple Myeloma; Prostatic Neoplasms, Castration-Resistant; Uveal melanoma; Anemia, Aplastic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Metabolic Diseases; Prostatic Neoplasms; Osteopetrosis; Osteosarcoma; Sarcoma; Blastic Plasmacytoid Dendritic Cell Neoplasm; Colorectal Neoplasms; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Myeloid, Acute; Lymphohistiocytosis, Hemophagocytic; Anemia, Sickle Cell; Leukemia, Biphenotypic, Acute; Leukemia, Lymphocytic, Chronic, B-Cell; Congenital Bone Marrow Failure Syndromes; Melanoma; Thalassemia; Leukemia, Myelogenous, Chronic; Bone Marrow Neoplasms; Leukemia; Hematologic Neoplasms; Lymphoma, B-Cell; Neoplasm, Residual; Solid tumours; Immunoproliferative Disorders; Leukemia, Lymphoid; Lymphatic Diseases; Primary Immunodeficiency Diseases; Anemia, Diamond-Blackfan; Graft vs Host Disease; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Myeloproliferative Disorders; Hemoglobinopathies; Fanconi Anemia; Neoplasms; Immune System Diseases
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyEarliest Brand NameEarliest Approval CountryEarliest IndicationEarliest Approval CompanyEarliest Approval DateIndicationClinical Trial
Tacrolimus HydrateLCP-Tacro; FR-900506; L-679934; FK-506MR; FK-506E; FK-506; MR-4; RTU-007ApprovedAstellas Pharma IncProtopy, Graceptor (as hydrate), Protopic, Prograf (as hydrate), Hecoria (as hydrate), Hexal, Envarsus XR, Talymus, 普乐可复, Advagraf, Envarsus, Modigraf, Astagraf XL, TacroBellUnited StatesRejection in heart transplantation; Rejection of renal transplantation; Rejection of liver transplantationAstellas Pharma Us Inc1994-04-08Keratoconjunctivitis; Dry Eye Syndromes; Conjunctivitis; Psoriasis; Pulmonary Arterial Hypertension; Amputation, Traumatic; Burns; Asthma; Surgical Wound Infection; Colitis, Ulcerative; Rejection in heart transplantation; Infertility, Female; Lupus Nephritis; Hamman-Rich Syndrome; Nephrotic Syndrome; Renal Insufficiency, Chronic; Wounds and Injuries; Vitiligo; Dermatitis, Atopic; Peripheral Nerve Injuries; Ocular inflammation; Edema; Encephalitis; Crohn Disease; Glomerulonephritis, IGA; Rejection of renal transplantation; Reperfusion Injury; Myasthenia Gravis; Medication Adherence; Keratoconjunctivitis Sicca; Genital Diseases, Male; Bone marrow transplant rejection; Liver Failure; Rejection of lung transplantation; Rejection of liver transplantation; Renal Insufficiency; Polymyositis; Primary Graft Dysfunction; Rejection of pancreatic transplantation; Keratoplasty rejection; Dermatomyositis; Kidney Diseases; Lupus Erythematosus, Cutaneous; Graft vs Host Disease; Arthritis, Rheumatoid; Lung Diseases, Intersti
Details
  • Product Inquiry
  • Marketed Drug Information
  • Clinical Drug Information
Share to:

Join UsLegalSite MapPrivacy PolicyTerms and Conditions
Website Feedback
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

order@acrobiosystems.com

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland